Evidence map›Paper›PMID 41194587›Full record

ArticleMolecular oncology2026

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells.

Juhyeon Son, Lily L Remsing Rix, Bin Fang, Eric A Welsh, Nicole V Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha-Coello, Yi Liao, Eric B Haura and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Juhyeon SonDepartment of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.ORCID 0009-0009-4774-4588
Lily L Remsing RixDepartment of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Bin FangProteomics and Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Eric A WelshBiostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Nicole V BremerDepartment of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, FL, USA.
Valentina FoglizzoDepartment of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, FL, USA.
Paola RoaDepartment of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, FL, USA.
Nickole Sigcha-CoelloDepartment of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, FL, USA.
Yi LiaoDepartment of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Eric B HauraDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Alexander DrilonThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
John M KoomenDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Emiliano CoccoDepartment of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, FL, USA.ORCID 0000-0002-1397-2656
Uwe RixDepartment of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.ORCID 0000-0002-8242-2770

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
2025 Catalyst award from the Sylvester Comprehensive Cancer CenterDepartment of Defense Lung Cancer Research Program W81XWH-22-1-0607Dwoskin family donationLung Cancer Research FoundationLung Cancer Research Foundation for the 2022 William C. Rippe AwardMadelon Ravlin Grant Memorial Award from the Woman's Cancer Association of the University of MiamiNational Cancer Institute/National Institutes of Health P30-CA008748NCI Cancer Center Support grant P30-CA076292NCI NIH HHS P30 CA008748Sylvester ACS Pilot ProjectTumor biology intra-programmatic pilot award from the Sylvester Comprehensive Cancer Center
6 · The paper itself

Abstract

Rearranged during transfection (RET) fusions drive subsets of non-small cell lung cancer (NSCLC) and papillary thyroid carcinoma (PTC). Despite new selective RET tyrosine kinase inhibitors (TKIs), resistance usually occurs and is often driven by RET-independent bypass mechanisms. Previous studies have implied crosstalk between RET and proto-oncogene tyrosine-protein kinase SRC, but the anticancer effects of targeting SRC combined with selective RET TKIs, and the underlying molecular mechanisms involved, are not fully understood. Our results show that the multitargeted SRC TKI dasatinib significantly enhanced the efficacy of RET TKIs in RET fusion-positive (RET

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-retsrc-Family KinasesCell Line, TumorDasatinibDrug SynergismHumansProto-Oncogene MasSignal TransductionThyroid Cancer, PapillaryThyroid NeoplasmsDasatinibMAS1 protein, humanOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene MasProto-Oncogene Proteins c-retRET protein, humansrc-Family Kinaseslung cancerphosphoproteomicsRETsignaling crosstalkSRCthyroid cancer

Identifiers

PMID41194587
PMCPMC13060644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.